Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
Brazil
Site 5071, Instituto de Puericultura e Pediatria Martagao Gesteira CRS, Rio de Janeiro India
Site 31441, BJMC CRS, Pune South Africa
Site 31976, PHRU Matlosana CRS, Klerksdorp, North West Site 31790, Desmond Tutu TB Centre (DTTC) CRS, Cape Town Site 31929, Sizwe CRS, Johannesburg